Plain-English translation of NCT06687837 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Parkinson Disease research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This Phase I trial is testing whether doctors can safely transplant autologous induced pluripotent stem cell-derived dopaminergic progenitor cells—lab-grown nerve cells created from your own skin cells—directly into your brain to help restore dopamine production and improve Parkinson's symptoms. The medication (the transplanted cells) would be custom-made just for you, grown in a laboratory, and then surgically placed into a specific brain region called the putamen. Over 2 years, researchers will monitor your safety and whether the treatment helps reduce your motor symptoms.
Current Parkinson's medications help many people, but their benefits often fade over time, leaving patients with uncontrolled symptoms and periods where medication doesn't work. This trial is exploring whether replacing damaged dopamine-producing cells with healthy new ones grown from your own tissue could offer a longer-lasting or more effective way to manage the disease.
You likely qualify if…
You likely don't qualify if…
If you qualify, doctors would first take a small skin sample to grow your custom transplant cells in the laboratory over several months. Once ready, you would undergo brain surgery under general anesthesia to have the cells implanted into both sides of your brain. After surgery, you would return for regular visits over 2 years—including physical exams, brain scans (MRI, CT, and PET imaging), and assessments of how well you are doing—to make sure the transplant is safe and working.
AI-generated summary from trial data · Jul 4, 2026 · Not medical advice
United States